Stock Rating Upgrade
The Value Trend Rating for CASI Pharmaceuticals Inc (NASDAQ: CASI) improved in recent days from C to B reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in our next report.
Recent Price Action
CASI Pharmaceuticals Inc (NASDAQ: CASI) stock declined by -4.7% on 3/18/24. The shares closed at $3.03. However, trading volume in this decline was exceptionally low at 27% of normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -37.8% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, CASI is expected to continue to be a modest Value Eraser.
CASI Pharmaceuticals has a current Value Trend Rating of B (Positive). This VT Rating improved in recent days from C previously. With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. CASI Pharmaceuticals has a slightly negative Appreciation Score of 33 but a very high Power Rating of 98, leading to the Positive Value Trend Rating.
Be the first to comment